Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. - Wikidata - awgldk - TriplyDB

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

http://www.wikidata.org/entity/Q33716402

about

Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2 SYK is a critical regulator of FLT3 in acute myeloid leukemia A decade of exploring the cancer epigenome - biological and translational implications Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics Epigenetic regulators and their impact on therapy in acute myeloid leukemia Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance Open access chemical probes for epigenetic targets MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management Synthesis of lysine methyltransferase inhibitors Structural and functional coordination of DNA and histone methylation Chemical probes of histone lysine methyltransferases Design of small molecule epigenetic modulators Targets, models and challenges in osteoarthritis research Epigenetics: the fine-tuner in inflammatory bowel disease?Mechanisms of epigenetic regulation of leukemia onset and progression Recent progress toward epigenetic therapies: the example of mixed lineage leukemia Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention Concise review: Leukemia stem cells in personalized medicine Current chemical biology approaches to interrogate protein methyltransferases The next steps in next-gen sequencing of cancer genomes Cancer epigenetics drug discovery and development: the challenge of hitting the mark Hijacked in cancer: the KMT2 (MLL) family of methyltransferases Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer Selective Inhibitors of Histone Methyltransferase DOT1L: Design, Synthesis, and Crystallographic Studies Potent inhibition of DOT1L as treatment of MLL-fusion leukemia Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models Structures of NS5 Methyltransferase from Zika Virus Cell-based assays to support the profiling of small molecules with histone methyltransferase and demethylase modulatory activity Epigenetic Therapeutics: A New Weapon in the War Against Cancer Emerging concepts of epigenetic dysregulation in hematological malignancies Histone lysine methyltransferases as anti-cancer targets for drug discovery Epigenetics in Cancer: A Hematological Perspective Epigenome-based personalized medicine in human cancer The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond

P2860

Q24300459-9EF87EF0-69BE-4C59-BDC8-5942E97C7849 Q24337247-0CC2E6A9-4FE4-4285-B3A9-39196E4D5708 Q24614467-0574DC48-AE04-4C16-B046-0AE8A8FE4B74 Q26744080-FDA3B2B5-3531-406B-8433-338A6420737F Q26744441-0876CC87-3B99-46FA-84C2-DBD905411EEA Q26746038-06616DA2-0F32-4473-BF57-A5D53418BCDE Q26749421-870C70EE-4B54-46BB-AD65-4341CBB20C8D Q26765402-79A6B3FD-DDE3-4434-AAFC-BDF7DDC12625 Q26769943-34B179E7-BA50-4287-B45C-F422979B73DA Q26776393-14005CAE-70B9-48CC-BDBD-57469B42B5A1 Q26781872-E2922E45-1D86-4FB9-97B3-348210B61101 Q26785379-8CB48110-E718-441D-8DB8-EE3579A37BA3 Q26799953-71DEE407-B6A7-44A6-89E3-888247CD458C Q26825534-5FE7C6A6-D8AB-42AD-B458-BFA96B408ACD Q26829218-1877CE7A-5E79-4822-92B4-4C1A736D6E5B Q26850027-10E701CC-1522-4B08-AD3D-472F81D8B9C1 Q26850147-DFC1FBA8-D924-4548-9008-C882566585F8 Q26853555-0C8D4135-3A04-4357-8730-6EFF56169EB0 Q26861785-EA655D23-C56F-489C-9A44-9A37E1695071 Q26863577-15E3582E-04A7-4277-BA93-C675F5E98530 Q26865149-05DE44C9-BAF1-46E5-AD5A-130E79CF3D77 Q26994739-07E8DE21-9BAF-4367-940B-4A357674F66B Q26995268-6037E617-C25D-4833-95D0-00125160E3C5 Q26995430-FBA30C99-3D18-4F9C-BFAC-D7543D284360 Q26998894-9595C802-B335-44FB-AD76-81E67D90A7AF Q27002333-C435F4D4-FFA2-434D-ABE4-3700D7CB3AD0 Q27006839-805F13DE-A4AB-480A-AEF7-A9CB8D708E0D Q27022720-ADC24749-058C-4F9F-895D-67073F394DE9 Q27674356-8AE4EBD6-76A2-43EB-B7BF-675C686A7A69 Q27678800-8569B661-5F16-4396-A5AA-1ED78FE9000F Q27682251-F4719E43-74EB-4A3E-A89D-5F221132F0E0 Q27700259-794A20C5-5E90-4D50-A75C-3172E0BC6A99 Q27928070-0A8E407B-3AF0-47CE-A46A-A85D62AE0EB3 Q28070111-F016CEB5-9E02-41CD-9ACF-CB0D393E739D Q28072370-FE70A939-8854-4DEE-8C9F-BBCD30D6B574 Q28074522-5DCB08E4-ED73-44CD-9ADB-106A9386F434 Q28076288-102207E7-FB62-4DA1-BB5C-E716DBAF5962 Q28077082-FF22F984-B015-43CC-A1A8-C42756AC44E9 Q28083951-D16C395A-EFAC-4A3C-9E02-EFA0716989C5 Q28085672-A61F4EAE-CC9E-41F4-A350-9F6D0B8BF3EC

P2860

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

http://www.wikidata.org/entity/Q33716402

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.

@ast

Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.

@en

type

label

Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.

@ast

Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.

@en

prefLabel

Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.

@ast

Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.

@en

P1433

Q33716402-94B22378-9204-446B-B42E-0E59A9E1E587

P1476

Q33716402-B84143CE-3BEF-4B6B-9CAE-8715B37B1AE7

P2093

Q33716402-0AA20E9E-D47D-4897-9424-069A365619F3

Q33716402-1B3F475F-AEBE-4D4D-A47A-5D8FF6DB3352

Q33716402-20F06B7F-0831-41DF-85B0-9378FC2A00B5

Q33716402-2531B4F4-D8BF-48CC-B45D-5D1D0B099A08

Q33716402-2674720C-68B3-4CEC-8937-EE7AF80EFC6F

Q33716402-35B2F124-F2DB-4088-AEDE-195A3B1909E2

Q33716402-53AC5C84-8F66-40F3-A995-0BEF1B82F831

Q33716402-677BB3A1-59F1-4B7A-BE08-6CFED6669EFC

Q33716402-696FA06B-BB9D-4B46-972C-1349C4A96542

Q33716402-703FCB70-C8A5-4F8D-87A3-588EA59B8AC0

P2860

Q33716402-06D84B17-08D2-4FAD-B86F-9967F058CC0D

Q33716402-115F733A-052A-4B09-8CBD-731A20834A3A

Q33716402-13027E3B-6818-42CF-8F4C-1AED668B16E9

Q33716402-13B76036-4495-41A8-8461-A6F9A976CA19

Q33716402-156C0A45-A897-4270-B0EE-9D0191E9864E

Q33716402-17009C2A-EF97-4C0E-BB57-400D1E7CA4D7

Q33716402-17BFEFFD-EEFD-4166-A4BB-8AC01E0253C4

Q33716402-18C61A8A-5BC1-4761-972D-3B2FF78CA283

Q33716402-2783ACFC-CF1F-4B1E-A436-4917941E8527

Q33716402-29B86A92-3F9F-4F68-AF04-37C2411AF7E0

P304

Q33716402-93B7CB88-65F4-4ADC-8A68-34572DFCDEE4

P31

Q33716402-E6FC0348-0AC5-4DA9-A664-293CB3109C65

P356

Q33716402-C4877D6B-E3A1-489E-8AB5-EE791B8AEA71

P433

Q33716402-05136C66-5898-4506-BA5C-1C53F2EF6E48

P478

Q33716402-D3D8DF1F-088D-4C9E-B73D-33445CA94677

P50

Q33716402-49D8CF1B-CC0F-4CD8-B3BA-33101666BE62

Q33716402-598B7E92-3E23-4649-BEA1-CD14342639D3

Q33716402-E91AA469-4641-4B5A-BA71-2EC47CB24109

P577

Q33716402-D76DBFED-6183-48B2-9D87-D39AFD04D041

P5875

Q33716402-190CEA6F-3DA9-4276-A5E7-58DDA154BFBD

P698

Q33716402-4D0205B3-54F4-4896-93AF-7E13EFD55A76

P921

Q33716402-5F0187FE-C393-4A6A-AD91-E8E5433F5F3A

P932

Q33716402-AA36744F-9C82-43D0-B237-A46182261EF6

P356

J.CCR.2011.06.009

P1433

P1476

Selective killing of mixed lin ...... small-molecule DOT1L inhibitor

@en

P2093

Carly A Therkelsen

http://www.w3.org/2001/XMLSchema#string

Christina R Majer

http://www.w3.org/2001/XMLSchema#string

Christopher J Sneeringer

http://www.w3.org/2001/XMLSchema#string

Edward J Olhava

http://www.w3.org/2001/XMLSchema#string

Jeffrey Song

http://www.w3.org/2001/XMLSchema#string

Jen-Chieh Tseng

http://www.w3.org/2001/XMLSchema#string

Jesse J Smith

http://www.w3.org/2001/XMLSchema#string

Kevin W Kuntz

http://www.w3.org/2001/XMLSchema#string

L Danielle Johnston

http://www.w3.org/2001/XMLSchema#string

Lei Jin

http://www.w3.org/2001/XMLSchema#string

P2860

A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription

Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom)

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization

DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells

hDOT1L links histone methylation to leukemogenesis.

Characterization of the DOT1L network: implications of diverse roles for DOT1L

Misguided transcriptional elongation causes mixed lineage leukemia

Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain

MLL targets SET domain methyltransferase activity to Hox gene promoters

P304

53-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2011.06.009

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Kathrin M. Bernt

Kathrin M Bernt

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51479220

http://www.w3.org/2001/XMLSchema#string

P698

21741596

http://www.w3.org/2001/XMLSchema#string

P921

P932

4046888

http://www.w3.org/2001/XMLSchema#string